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did not directly influence reduced motivation. Symptoms of 
depression mediated the impact of disease severity on gen-
eral fatigue (β = 0.25), on reduced activity (β = 0.31) and on 
mental fatigue (β = 0.28), but not on physical fatigue. Re-
duced motivation was not mediated, but directly influenced 
by more symptoms of depression (β = 0.82).  Discussion: 
Since increased symptoms of depression mediate the im-
pact of disease severity on three domains of fatigue in PD 
patients, disease management should focus on the treat-
ment of PD and symptoms of depression. 
 Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Fatigue has become a clinically important factor in ex-
plaining quality of life (QoL) in patients suffering from 
Parkinson’s disease (PD)  [1, 2] . Fatigue has been com-
monly reported in PD, affecting as many as 37–56%  [3] 
or even to two-thirds of PD patients  [1, 4] , although phys-
ical and mental fatigue were also prevalent in the healthy 
population  [5] . Those PD patients who suffer from fa-
tigue perceive it as a symptom with a very high impact on 
 Key Words 
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 Abstract 
 Purpose: Fatigue is a frequent non-motor complaint of pa-
tients with Parkinson’s disease (PD). Despite increasing 
knowledge on fatigue, the factors leading to its develop-
ment are still not recognised. The aim of this investigation 
was to test, using structural equation modelling, the hy-
pothesis that the influence of disease severity on fatigue is 
mediated by symptoms of depression in patients with PD. 
 Method: The sample consisted of 190 PD patients (93 men, 
48.9%, mean age 68.2 ± 9.3 years, mean disease duration 
6.4 ± 4.7 years) recruited from hospitals and outpatient clin-
ics in the East Slovakia region. The Multidimensional Fatigue 
Inventory, the Hospital Anxiety and Depression Scale and 
the Unified Parkinson’s Disease Rating Scale were used. 
 LISREL was used to analyse the data.  Results: Disease sever-
ity was directly associated with symptoms of depression (β = 
0.26) and directly affected fatigue in terms of increased lev-
els of general fatigue (β = 0.35), physical fatigue (β = 0.22), 
reduced activity (β = 0.31) and mental fatigue (β = 0.29), but 
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their daily functioning  [4] or QoL  [2] . Mood disorders 
such as anxiety and depression are associated with poor 
health-related quality of life (HRQoL) in PD  [6] .
 Cross-sectional prevalence estimates for anxiety and 
depression in PD have shown proportions ranging from 
30 to 50% for each disorder  [7–9] whilst older epidemio-
logic studies on depression in PD have prevalence rates 
ranging from 2.7% to more than 90%  [10, 11] . Further-
more, in the age group comparable to PD patients, the 
prevalence of symptoms of depression was estimated to 
be 13.5% in the general population, while the prevalence 
rates for anxiety disorders ranged between 1.2 and 14% 
 [12] . One French study  [13] of prevalence rates of anxiety 
and depression in PD patients and in patients with other 
disorders showed that patients with higher symptoms of 
anxiety (Hospital Anxiety and Depression Scale (HADS)-
Anxiety >8 symptoms) were more prevalent in PD (51 vs. 
29%) than patients with higher symptoms of depression 
(HADS-Depression >8 symptoms) (40 vs. 10%). The dif-
ference between the proportions of PD patients and non-
PD patients with enhanced symptoms of anxiety (22.4%) 
may vary between 12.2 and 32.5% (95% CI) in the popu-
lation, whereas the difference in the proportions of those 
with depression (29.8%) was estimated to vary between 
22.2 and 37.4%.
 Symptoms of depression and fatigue are simultane-
ously associated with many illnesses, but in particular 
with cancer  [14, 15] , chronic heart failure  [16] , multiple 
sclerosis  [17–21] and PD  [22–24] . Increased symptoms of 
depression have a great impact on the course of PD in 
terms of functional status, activities of daily life and 
HRQoL  [6] . In the last decade the relationships between 
fatigue, disease severity and depression have been inves-
tigated in PD patients and have shown strong correla-
tions. Hagell and Brundin  [3] found that depression and 
anxiety were the main predictors of fatigue (Functional 
Assessment of Chronic Illness Therapy-Fatigue scale, 
FACIT-F) and that fatigue was associated with a lack of 
motivation, disease severity (Unified Parkinson’s Disease 
Rating Scale (UPDRS)) and pain; however, they conclud-
ed that the role of anxiety was in contrast to what has been 
previously documented. Friedman and Friedman  [25] 
showed in a 9-year follow-up study that fatigue was not 
correlated with disease severity or duration but with de-
pression. Several studies reported that both symptoms of 
depression and fatigue are associated with a poor QoL 
 [26] . In a study by Lou et al.  [27] , symptoms of depression 
were associated with all domains of fatigue as assessed us-
ing the MFI-20, except physical fatigue, and disease sever-
ity did not correlate with any of the domains of fatigue.
 However, there is some overlap between fatigue and 
mood disorders, as fatigue is one of the DSM-IV criteria 
for both depression and anxiety. A recent paper by Skor-
vanek et al.  [28] addressed the issue of primary fatigue, 
i.e. fatigue in the absence of depression, anxiety and ex-
cessive daily somnolence (EDS), and secondary fatigue, 
i.e. fatigue in the presence of depression or anxiety or 
EDS. In their study they found that both types of fatigue 
can be clearly distinguished and that they are associated 
with different clinical determinants.
 As the associations between disease severity, depres-
sion and fatigue in patients with PD were predominantly 
based on bi- and multivariable analyses, we now report 
findings of path analyses conducted to explore the rela-
tionships between disease severity and symptoms of de-
pression as factors that are generally considered as pre-




 All eligible PD patients in the database records from outpatient 
neurologists and hospitals were asked for participation by means 
of a mailed questionnaire comprised of questions on sociodemo-
graphic background, medical history, current medication and self-
report questionnaires among which were the HADS and the Mul-
tidimensional Fatigue Inventory (MFI-20).
 Three weeks after receipt of the questionnaires and written in-
formed consent, all patients were invited for an interview on rel-
evant issues that were not part of the questionnaires and were 
checked for inclusion and exclusion criteria. After this structured 
interview, a neurologist assessed the disease severity of each pa-
tient using UPDRS Version 3.0  [29] , including Hoehn & Yahr 
(H&Y) staging  [30] and the Schwab and England Disability Scale 
 [31] . All of the examined patients were in the ON stage during the 
interview and neurological examination. Patients who were not 
able to fill in the questionnaires due to impairment of their vision 
or motor impairment of their hands answered the questions dur-
ing an oral interview. Caregivers were not allowed to provide ques-
tionnaires inputs.
 Patients 
 This cross-sectional study evaluated symptoms of anxiety and 
depression, disease severity and fatigue in a study population of 
190 patients with PD. The patients were recruited from one hospi-
tal (17 patients) and 18 neurology outpatient clinics (173 patients) 
in the East Slovakia region between February 2004 and November 
2007. All patients were diagnosed in accordance with the UK PD 
Society Brain Bank Clinical Criteria  [32] and their mental abilities 
were assessed with the Mini-Mental State Examination (MMSE) 
 [33] . Exclusion criteria were as follows: (i) MMSE <24, as well as a 
negative response to an acute  L -dopa challenge; (ii) secondary par-
kinsonism; (iii) sign of brain ischemia revealed by computer to-
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and (v) severe comorbidity associated with the study variables – 
severe diseases where we expected patients not to survive for at 
least 4 years, or which could confound the main variables in our 
study, such as QoL and fatigue (e.g. rheumatoid diseases, end-stage 
renal diseases and others). The study was approved by the local 
Ethics Committee. Informed consent was obtained from each pa-
tient prior to the study.
 Measures 
 Sociodemographic and Clinical Characteristics: Sociodemo-
graphic and clinical characteristics included age, gender, marital 
status, medical history and current medication, all of which were 
retrieved from patient records.
 Fatigue 
 MFI-20: Fatigue was assessed using the MFI-20 as the pri-
mary outcome measure. The MFI is a widely used 20-item self-
report instrument with good psychometric properties. It mea-
sures five domains of fatigue: general fatigue (referring to the 
general functioning of the subject, with statements such as ‘I feel 
tired’), physical fatigue (somatic sensations directly referring to 
tiredness, for instance, ‘Physically I feel only able to do a little’), 
mental fatigue (referring to cognitive symptoms such as having 
difficulty in concentration, for instance, ‘It takes a lot of effort to 
concentrate on things’), reduced motivation (reflecting the mo-
tivation to start any activity, such as ‘I dread having to do things’) 
and reduced activity (a potential consequence of subjective fa-
tigue, such as ‘I think I do very little in a day’). Each domain 
contains 4 items, and the score on each item ranges from 1 (no 
fatigue) to 5 (very fatigued). The score for each domain ranges 
from 4 (no fatigue) to 20 (highest possible fatigue). The time 
frame is the last few days. MFI scales have shown good psycho-
metric properties across several chronic diseases and languages 
 [34–36] and good internal consistency (Cronbach’s α across 
scales ranging from 0.80 to 0.94). In the current study, Cron-
bach’s α yielded 0.72–0.84, which were all above what is mini-
mally acceptable given the scale length and the average inter-
item correlation  [37–41] .
 Anxiety and Depression 
 HADS: Depression was assessed using the HADS. This self-
administered scale simultaneously assesses symptoms of anxiety 
(HADS-A) and of depression (HADS-D). It consists of 14 items (7 
for the assessment of anxiety and 7 for depression). All items are 
answered on a 4-point Likert scale from 0 (no problem) to 3 (ex-
treme problem) with a score range of 0–21. The HADS is a reliable 
questionnaire that performs well in screening for the separate di-
mensions of anxiety and depression  [42] and has been validated in 
PD study populations  [13, 43–45] . In the present study, Cron-
bach’s α was 0.70 for anxiety and 0.79 for the depression subscales. 
A cut-off score >8 for both subscales was used to quantify patients 
with likely anxiety and depressive symptoms, as this cut-off yields 
an optimal balance between sensitivity and specificity  [42] .
 Four psychological distress symptom groups were defined by 
employing the classification of Pedersen et al.  [46] and Bartels et 
al.  [47] , who evaluated differences in HRQoL between these groups 
in tinnitus patients. These four independent symptom groups 
were defined as: (1) no symptoms of anxiety and depression, (2) 
symptoms of anxiety-only, (3) depression-only and (4) anxiety + 
depression.
 Disease Severity 
 The UPDRS is a four-subscale combined instrument for assess-
ing mental state, activities of daily living, motor examination and 
complications.
 Two further instruments are used together with the UPDRS, 
namely: (1) a modified H&Y staging and (2) the Schwab and 
 England Scale. It is currently used as a standard reference scale in 
clinical practice and research  [19–21] . We used the UPDRS-III 
section for our research.
 Data Analyses 
 Fisher’s exact test and the difference between proportions test 
 [48] were used to compare H&Y staging groups on  demographic 
and clinical characteristics and are presented as numbers and per-
centages. Continuous variables were normally distributed in the 
current study (Shapiro-Wilk, p > 0.05) and were therefore com-
pared with Student’s t test and are presented as mean ± SD. Because 
we were interested in whether the implications of co-occurrence of 
anxiety and depression had a stronger impact on fatigue when com-
pared with single or no occurrence of anxiety or depression, levels 
of fatigue in subjects with no symptoms of psychological distress 
were compared with levels of fatigue in patients classified as having 
only symptoms of anxiety, only symptoms of depression as well as 
symptoms of both anxiety and depression. A post hoc test (with 
Bonferroni correction for capitalisation on chance in multiple test-
ing) was applied to all tests to adjust for multiple comparisons, with 
p < 0.01 (p < 0.05/5 items) indicating statistical significance.
 Cohen’s effect size (ES) for unrelated groups was used to esti-
mate the magnitude of the difference between two groups (mean 
difference score/the pooled standard deviation). According to Co-
hen’s thresholds, an ES of <0.20 indicates a trivial difference, an ES 
of  ≥ 0.20 to <0.50 a small difference, an ES of  ≥ 0.50 to <0.80 a mod-
erate difference, and ES  ≥ 0.80 a substantial difference  [49] .
 Next, a path model was analysed to test the estimates of the 
magnitude of the effects of disease severity and depression on the 
five dimensions of fatigue and to estimate whether our data fit the 
hypothesised model using structural equation modelling (SEM). 
SEM allows the inclusion of unidirectional effects, but no recipro-
cal relationships can be tested. Therefore, SEM is more appropriate 
for our study than standard multiple regression technique as it al-
lows for simultaneous assessment of the strength and direction of 
the interrelationships among multiple dependent (MFI domains) 
and independent variables (UPDRS and Depression). SEM does 
not prove causality, but it tests whether the dataset, with its inher-
ent covariance structure, supports or rejects the postulated direct 
and indirect effects or relationships between variables and has 
been advocated as the best approach in mediating models  [50, 51] .
 For determining the model fit, we used multiple criteria as sug-
gested by Bentler and Bonett  [52] . Using LISREL 8.7, we tested a 
recursive model (see  fig. 1 ) in which pathways go directly from the 
background (exogenous) variable disease severity (UPDRS) to the 
five dimensions of fatigue (MFI), and a pathway through which 
symptoms of depression mediate the influence of disease severity 
(UPDRS) on the extent of self-reported fatigue (MFI-20). To allow 
for mutual comparisons between the path coefficients, a complete-
ly standardised solution was used. The analysis was done with SEM 
using the maximum likelihood method. The fit of the model was 
evaluated by means of (i) the comparative fit index (CFI), (ii) the 
normed fit index (NFI), (iii) the non-normed fit index (NNFI), (iv) 



















   
   
   
   
   
   
   
   
   
























mean square error of approximation (RMSEA) and (vi) the χ 2 
test; a non-significant χ 2 indicates that a non-significant amount 
of variance in the data remains unexplained. An adequate fit of 
the  model is indicated by NFI, NNFI and CFI  ≥ 0.90, while 
SRMR <0.08, RMSEA <0.05 and NFI >0.90 are considered to indi-
cate a good fit. The model was evaluated by examining the param-
eter estimates and measures of overall fit provided by LISREL. A 
residual correlation between depression and reduced motivation 
and between the domains of fatigue was allowed, since stan-
dardised residuals indicated that this correlation exists (not de-
picted). Only the path coefficients significant at the p < 0.05 level 
are depicted in the final model.
 Results 
 Out of the 332 patients with PD who met the inclusion 
criteria, 126 did not respond to the invitation. Of the 206 
who agreed to participate, 7 patients were eliminated be-
cause of the exclusion criteria and 9 patients refused to 
participate after written informed consent, thus leaving 
190 for analysis (response rate 57.2%). Non-respondents 
did not differ significantly from the analysed group either 
in age (mean difference 1.6 years, 95% CI –0.80 to 4.0 
years) or gender (Fisher’s exact test, p = 0.08), with a dif-
ference between proportions of 9% (95% CI –3.0 to 12.4%). 
The mean age of the patients at baseline was 68.2 ± 9.3 
years; the mean age at disease onset was 59.5 ± 11.1 years, 
and the mean disease duration was 6.4 ± 4.7 years.
 Differences in Sociodemographic and Clinical 
Characteristics and Fatigue Measures across H   Y 
Subgroups 
 The use of dopamine agonists was more prevalent 
among patients classified as H&Y <2, whereas the simul-
taneous use of  L -dopa + COMT inhibitors,  L -dopa + do-
pamine agonists and  L -dopa + COMT inhibitors + dopa-
mine agonists was more prevalent among patients classi-
fied as H&Y  ≥ 2. Other pharmaceutical treatment regimens 
were more prevalent among H&Y <2 patients.
 Patients classified as H&Y  ≥ 2 had on average longer dis-
ease duration (H&Y  ≥ 2: 7.4 years vs. H&Y <2: 5.8 years) 
and had for all domains more symptoms of fatigue with 






































 Fig. 1. A path model of disease severity and symptoms of depression as predictors of domains of fatigue assessed with the MF-20 in PD 
patients. Coefficients are all statistically significant:  * *  < 0.01. n = 190, χ 2 = 6.58, d.f. = 5, p = 0.25, χ 2 /d.f. = 1.06, NNFI = 0.98, CFI = 1.00, 
NFI = 0.99, SRMR = 0.020, RMSEA = 0.045. 
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 Details of the sociodemographic and clinical charac-
teristics of the patients stratified by H&Y staging are 
shown in  table 1 .
 Differences in Domains of Fatigue across 
Psychological Distress Subgroups 
 Table 2 presents the results of bivariate evaluation of 
differences in domains of fatigue measures between the 
four psychological symptom groups. Levels of general fa-
tigue, physical fatigue, reduced activity, reduced motiva-
tion and mental fatigue were compared across the follow-
ing independent subgroups: (1) anxiety-only, (2) depres-
sion-only and (3) anxiety + depression, which were 
compared with (4) patients without symptoms of psycho-
logical distress as a reference group.
 Differences in levels of fatigue between no-symptoms 
and anxiety + depression subgroups (A–D) were large for 
all domains of fatigue (ES: 0.86–1.15), whereas differenc-
es in levels of fatigue were moderate between no-symp-
toms and depression-only (A–C), with ES ranging from 
0.52 to 0.73 for the domains of general, physical and men-
tal fatigue and reduced activity. Those patients who were 
classified as having only depressive symptoms showed a 
large difference compared with the group having no-
symptoms. Moreover, upon comparing anxiety-only pa-
tients with patients having no symptoms of psychological 
distress (A, B), all differences proved to be due to random 
fluctuation (p > 0.01) after correction for multiple testing.
 No differences in fatigue were found between those 
who reported no symptoms of psychological distress and 
those who reported only symptoms of anxiety. Therefore, 
we only used symptoms of depression in the model in re-
lation to disease severity and fatigue.  Figure 1 depicts the 
results of path analysis with LISREL 8.7, which shows the 
direct paths between disease severity (UPDRS) and de-
pression (HADS) and the five domains of fatigue (MFI-
20) as well as the mediated paths, which show the influ-
ence of disease severity on the domains of fatigue through 
higher numbers of symptoms of depression. Disease se-
verity directly influenced symptoms of depression (β = 
0.26) and directly affected fatigue in terms of more symp-
toms of general fatigue (β = 0.35), physical fatigue (β = 
0.22), reduced activity (β = 0.31) and mental fatigue (β = 
0.29), though it did not directly influence reduced moti-
vation. However, more symptoms of depression mediat-
ed this impact of disease severity on more symptoms of 













0.15 –18.3 to 10.8
Antiparkinsonian therapy, n (%)
L-Dopa 9 (7.83) 11 (14.67) 0.11 –16.2 to 2.55%
Dopamine agonists 31 (26.96) 5 (6.67) 0.40 10.4 to 30.2%
L-Dopa + COMT inhibitors 8 (6.96) 15 (20.0) 0.19 23.2 to 28.7%
L-Dopa + dopamine agonists 11 (9.56) 15 (20.0) 0.10 6.0 to 20.6% 
L-Dopa + COMT inhibitors + dopamine agonists 9 (7.83) 14 (18.67) 0.14 7.1 to 20.9%
Other 47 (40.87) 15 (20) 0.31 8.1 to 33.6%
mean ± SD mean ± SD p value2 (ES)3 95% CI ES
Age, mean ± SD 67.5±8.6 69.7±10.3 0.178
Disease duration 5.8±4.2 7.4±5.4 0.023 (0.34) 0.15 to 0.63
HADS-D 6.2±3.4 7.7±4.0 0.008 (0.42) 0.12 to 0.70
MFI – General fatigue 13.1±3.9 14.7±3.8 0.007 (0.41) 0.13 to 0.71
MFI – Physical fatigue 13.4±3.4 15.0±3.8 0.003 (0.45) 0.15 to 0.74
MFI – Reduced activity 11.7±3.4 13.8±3.8 0.000 (0.60) 0.29 to 0.88
MFI – Reduced motivation 10.4±3.4 11.6±4.4 0.049 (0.32) 0.12 to 0.61
MFI – Mental fatigue 11.2±3.5 12.8±4.0 0.007 (0.43) 0.14 to 0.72



















   
   
   
   
   
   
   
   
   
























general fatigue (β = 0.25), more symptoms of reduced ac-
tivity (β = 0.31) and more symptoms of mental fatigue 
(β = 0.28). Reduced motivation was not mediated but di-
rectly influenced by more symptoms of depression (β = 
0.82). More symptoms of physical fatigue in PD patients 
were not affected by higher levels of depression.
 Discussion 
 The aim of our study was to test, using SEM, the hy-
pothesis that the influence of disease severity on fatigue 
is mediated by symptoms of depression in patients with 
PD. We found (i) that disease severity is not a predictor 
of fatigue in terms of reduced motivation, but (ii) it is a 
precursor of more symptoms of general fatigue, physical 
fatigue, reduced activity and mental fatigue. Disease se-
verity (iii) directly influenced symptoms of depression, 
and symptoms of depression (iv) mediated the impact of 
disease severity on higher levels of perceived general fa-
tigue, more feelings of reduced activity and perceiving 
more mental fatigue. Symptoms of depression also (v) 
directly determined more symptoms of reduced motiva-
tion without the influence of disease severity. Finally, 
more physical fatigue in PD patients (vi) was not affected 
by more symptoms of depression. Symptoms of anxiety 
were not associated with MFI-20 domains of fatigue 
which was probably an effect of the fact that patients with 
enhanced fatigue are more at risk to develop symptoms 
of depression and less likely to develop symptoms of anx-
iety. This seems in contrast with previous results from 
this study.
 Our results show that disease severity is a precursor of 
increased levels of general fatigue, physical fatigue, re-
duced activity and mental fatigue, but that disease sever-
ity is not related to fatigue in terms of reduced motivation. 
Furthermore, disease severity directly increased symp-
toms of depression. Mental fatigue and depression were 
generally considered to be independent of disease severity, 
whereas other studies have found an association between 
poor UPDRS and more symptoms of fatigue. In a longitu-
dinal study, Alves et al.  [53] found fatigue, measured by 
the generic Nottingham Health profile, to be related to 
disease severity. In a previous study, we found disease se-
verity associated with worse fatigue in all fatigue domains 
as measured with the MFI  [54] . In a recent study, Skor-
vanek et al.  [28] found that none of the fatigue domains in 
primary fatigue (i.e. fatigue in the absence of a mood dis-
order or EDS) as measured by the MFI was associated with 
a worse UPDRS-III score. However, in the secondary fa-
tigue group (i.e. fatigue in the presence of a mood disorder 
or EDS) they found that UPDRS-III scores were signifi-
cantly related to all fatigue domains except mental fatigue. 
In the ELLDOPA trial  [55] , where untreated non-dement-
ed and non-depressed PD patients were examined, fatigue 
worsened significantly more in the placebo group than in 
the  L -dopa groups, and some other studies have suggested 
a potential effect of dopaminergic treatment on at least 
some aspects of fatigue  [56, 57] . However, fatigue in PD is 
generally considered to be a non-dopaminergic symptom. 
In fact, most studies have thus far not found any signifi-
cant association between dopaminergic treatment or dai-
ly  L -dopa equivalent dose and fatigue  [24, 28, 53] . Simi-
larly, we did not find an association between fatigue and 

















F  Effect size
A– D A–C A–B
General fatigue 12.04±3.89 13.74±3.43 14.68±3.57 16.33±3.22 12.40*** 1.15*** 0.70** ns
Physical fatigue 12.63±3.67 13.01±3.24 15.00±2.36 15.94±3.44  8.96*** ns** 0.68** ns**
Reduced activity 11.23±3.719 12.97±3.87 13.88±3.44 14.42±3.37  6.96*** 0.88** 0.73** ns
Reduced motivation 9.79±3.53 10.07±3.28 13.42±3.59 12.97±4.04 10.24*** 0.86*** 1.02** ns
Mental fatigue 10.50±3.47 12.38±3.97 12.35±4.08 14.00±2.78  8.55*** 1.06*** 0.52** ns
 A post hoc Bonferroni correction was applied to all tests to adjust for multiple comparisons, with p < 0.01 (0.05/5) indicating statis-
tical significance. Difference between groups with anxiety alone (A), depression alone (B) or no symptoms (C) were compared to the 
group with co-occurring symptoms of anxiety and depression (D) by means of ANOVA. F values are all significant at p = 0.01 level. 
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dopaminergic medication in our study (results not shown). 
The non-dopaminergic origin of fatigue in PD is also sup-
ported by the results of the previously mentioned 
 ELLDOPA study  [55] , where fatigue scores did not cor-
relate with the [ 123 I]-β-CIT SPECT striatal dopamine 
transporter density. Also, in a PET study conducted by 
Pavese et al.  [58], an association between fatigue and a 
relative serotonergic denervation in the basal ganglia and 
associated limbic circuits and F-dopa uptake reduction in 
the insular region, but not in the basal ganglia, was found, 
thus suggesting a serotonin-related basis for fatigue in PD.
 Several studies have shown a relationship between fa-
tigue and depression and our previous study in 150 PD pa-
tients also had similar results  [1] . Recently, Hagell and 
Brundin  [3] found that depression is a main predictor of 
fatigue. Our results show that more symptoms of depres-
sion are associated with reduced motivation, and that 
symptoms of depression mediate the impact of worse func-
tional status on mental fatigue, reduced activity and gen-
eral fatigue. As was found in the study of Skorvanek et al. 
 [28] , PD patients with depression had both higher UPDRS-
III scores and fatigue scores in all fatigue domains com-
pared with primary fatigue; however, once depressed pa-
tients were selected, depression did not play a further role 
in determining fatigue in this group of patients. Their find-
ings are in accordance with some other studies, which have 
found worse motor and fatigue symptoms in depressed pa-
tients  [59] . From this point of view, secondary fatigue prob-
ably presents a more severe phenotype of PD with worse 
functional status, as well as more non-motor symptoms, 
such as depression and anxiety. On the other hand, more 
research is needed to reveal the underlying mechanisms of 
primary fatigue in the absence of depression.
 Strengths and Limitations 
 One limitation of our study is the relatively low re-
sponse rate. Patients were recruited mostly from outpa-
tient neurologists, not from a specialised centre for PD 
care, and only those who agreed to participate were in-
cluded. For this reason, only patients with better overall 
functional status came for the examination and interview. 
As a consequence, the current study comprised patients 
with lower UPDRS motor scores, while patients with se-
vere disease were poorly represented in this study. How-
ever, we do not believe that this limits our observations. 
Although our results cannot be generalised to PD patients 
with all types of disease severity, we provide evidence that 
even in this selected population of PD patients, fatigue is 
already a serious problem. We decided to use a generic 
measure with a multidimensional design instead of a dis-
ease-specific fatigue measure, as this has the advantage of 
the possibility of using a generic instrument for different 
patient groups and consequently of comparing them. The 
association between depression and fatigue is still contro-
versial because of the possible overlap in symptomatology 
between PD and major depression: fatigue and sleep 
problems are among the diagnostic criteria for both. 
However, to control for conceptual correlation between 
fatigue, depressive symptoms and parkinsonism, both 
factors were specified as an independent, one-directional 
contributor to fatigue and not as a recursive relationship 
in the path model used for this study. Moreover, a previ-
ous study using UPDRS and depression symptoms 
showed no multicollinearity as independent variables of 
fatigue assessed with the MFI-20 (variance inflation fac-
tor and tolerance values are 0.58 and 1.13, respectively).
 Implications 
 Our study shows that disease severity predicts four do-
mains of fatigue, but the presence of depression mediates 
this impact to three domains of fatigue and that disease 
severity and depression independently predict two of 
these domains. Evidence-based strategies on management 
of PD fatigue are scarce. Thus, in secondary fatigue an ef-
fort should be made to properly manage motor symptoms 
and depression, since at least some patients might benefit 
from these measures. Drug trials focused on depression in 
PD should include fatigue scales as secondary outcome 
measures, as only limited evidence in this regard is avail-
able, and some studies which have been conducted have 
thus far not found any significant improvement in fatigue 
symptoms after antidepressant treatment despite im-
provement of depression  [60] . Further research, both 
cross-sectional and longitudinal, should be conducted in 
order to better understand the relationships between both 
primary and secondary fatigue and its influencing factors. 
Understanding this relationship is important, as it may 
influence the future clinical management of PD patients.
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